MSA - Multiple System Atrophy
17
7
10
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (17)
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
Neurologic Stem Cell Treatment Study
Invasive Home Ventilation in Denmark
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
The CurePSP Genetics Program
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
MotIoN aDaptive Deep Brain Stimulation for MSA
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis
Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
Modifiable Variables in Parkinsonism (MVP)